Researchers at University of Utah Health have discovered a potential therapeutic target for acute kidney injury (AKI), a condition that significantly increases the risk of chronic kidney disease and affects over half of ICU patients. Their preclinical studies indicate that ceramides, fatty molecules that damage kidney mitochondria, play a crucial role in triggering AKI. By genetically modifying ceramide production or using a ceramide-lowering drug, the team was able to preserve mitochondrial function and prevent kidney injury in mice, a finding that could reshape treatment strategies for AKI.
Scott Summers, PhD, leading the research, highlighted the remarkable reversal of AKI pathology through ceramide inactivation. The study, published in Cell Metabolism, suggests that monitoring urinary ceramide levels could serve as an early biomarker for AKI, particularly in high-risk patients undergoing procedures like heart surgery. Current diagnostic methods are often delayed and lack sensitivity, making the identification of urinary sphingolipids a promising avenue for improving AKI detection.
While the findings are promising, the researchers caution that further studies are necessary to ensure safety before advancing to human trials. If successful, this approach could not only mitigate AKI but also address mitochondrial dysfunction in various diseases, potentially transforming therapeutic options across multiple clinical areas.
Get started today with Solo access →
